CN114152754B - 一种用于检测人Dsg1 IgG抗体的ELISA试剂盒及其应用 - Google Patents
一种用于检测人Dsg1 IgG抗体的ELISA试剂盒及其应用 Download PDFInfo
- Publication number
- CN114152754B CN114152754B CN202111420932.8A CN202111420932A CN114152754B CN 114152754 B CN114152754 B CN 114152754B CN 202111420932 A CN202111420932 A CN 202111420932A CN 114152754 B CN114152754 B CN 114152754B
- Authority
- CN
- China
- Prior art keywords
- dsg1
- elisa kit
- polypeptide
- polypeptides
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101100010421 Mus musculus Dsg1a gene Proteins 0.000 title claims abstract description 45
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 41
- 238000008157 ELISA kit Methods 0.000 title claims abstract description 25
- 229920001184 polypeptide Polymers 0.000 claims abstract description 43
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 43
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 43
- 210000002966 serum Anatomy 0.000 claims abstract description 41
- 239000000243 solution Substances 0.000 claims abstract description 25
- 102000004190 Enzymes Human genes 0.000 claims abstract description 17
- 108090000790 Enzymes Proteins 0.000 claims abstract description 17
- 241000721454 Pemphigus Species 0.000 claims abstract description 17
- 239000011248 coating agent Substances 0.000 claims abstract description 16
- 238000000576 coating method Methods 0.000 claims abstract description 16
- 239000000427 antigen Substances 0.000 claims abstract description 14
- 102000036639 antigens Human genes 0.000 claims abstract description 14
- 108091007433 antigens Proteins 0.000 claims abstract description 14
- 239000011535 reaction buffer Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 201000011152 Pemphigus Diseases 0.000 claims abstract description 10
- 201000001976 pemphigus vulgaris Diseases 0.000 claims abstract description 8
- 239000011159 matrix material Substances 0.000 claims abstract description 7
- 239000012089 stop solution Substances 0.000 claims abstract description 6
- 239000003085 diluting agent Substances 0.000 claims abstract description 3
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000011534 wash buffer Substances 0.000 claims description 8
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- 238000007865 diluting Methods 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 2
- 238000002965 ELISA Methods 0.000 abstract description 8
- 102000004169 proteins and genes Human genes 0.000 abstract description 7
- 108090000623 proteins and genes Proteins 0.000 abstract description 7
- 238000003119 immunoblot Methods 0.000 abstract description 6
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 3
- 239000000872 buffer Substances 0.000 abstract description 3
- 238000004140 cleaning Methods 0.000 abstract description 3
- 239000012634 fragment Substances 0.000 abstract description 2
- 238000003759 clinical diagnosis Methods 0.000 abstract 1
- 238000001514 detection method Methods 0.000 description 19
- 238000005406 washing Methods 0.000 description 10
- 239000000523 sample Substances 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 5
- 102000005708 Desmoglein 1 Human genes 0.000 description 4
- 108010045579 Desmoglein 1 Proteins 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 206010034277 Pemphigoid Diseases 0.000 description 3
- KBLYJPQSNGTDIU-LOKLDPHHSA-N Thr-Glu-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N)O KBLYJPQSNGTDIU-LOKLDPHHSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- SYFHFLGAROUHNT-VEVYYDQMSA-N Arg-Thr-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O SYFHFLGAROUHNT-VEVYYDQMSA-N 0.000 description 2
- JAHCWGSVNZXHRR-SVSWQMSJSA-N Cys-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)N JAHCWGSVNZXHRR-SVSWQMSJSA-N 0.000 description 2
- KKBWDNZXYLGJEY-UHFFFAOYSA-N Gly-Arg-Pro Natural products NCC(=O)NC(CCNC(=N)N)C(=O)N1CCCC1C(=O)O KKBWDNZXYLGJEY-UHFFFAOYSA-N 0.000 description 2
- 208000027086 Pemphigus foliaceus Diseases 0.000 description 2
- 108010013835 arginine glutamate Proteins 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 208000000594 bullous pemphigoid Diseases 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 108010079547 glutamylmethionine Proteins 0.000 description 2
- 108010053725 prolylvaline Proteins 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000013215 result calculation Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XWTNPSHCJMZAHQ-QMMMGPOBSA-N 2-[[2-[[2-[[(2s)-2-amino-4-methylpentanoyl]amino]acetyl]amino]acetyl]amino]acetic acid Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(=O)NCC(O)=O XWTNPSHCJMZAHQ-QMMMGPOBSA-N 0.000 description 1
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 1
- STACJSVFHSEZJV-GHCJXIJMSA-N Ala-Asn-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O STACJSVFHSEZJV-GHCJXIJMSA-N 0.000 description 1
- SDZRIBWEVVRDQI-CIUDSAMLSA-N Ala-Lys-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O SDZRIBWEVVRDQI-CIUDSAMLSA-N 0.000 description 1
- AENHOIXXHKNIQL-AUTRQRHGSA-N Ala-Tyr-Ala Chemical compound [O-]C(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H]([NH3+])C)CC1=CC=C(O)C=C1 AENHOIXXHKNIQL-AUTRQRHGSA-N 0.000 description 1
- VWVPYNGMOCSSGK-GUBZILKMSA-N Arg-Arg-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O VWVPYNGMOCSSGK-GUBZILKMSA-N 0.000 description 1
- UFBURHXMKFQVLM-CIUDSAMLSA-N Arg-Glu-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O UFBURHXMKFQVLM-CIUDSAMLSA-N 0.000 description 1
- WVNFNPGXYADPPO-BQBZGAKWSA-N Arg-Gly-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O WVNFNPGXYADPPO-BQBZGAKWSA-N 0.000 description 1
- ATABBWFGOHKROJ-GUBZILKMSA-N Arg-Pro-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O ATABBWFGOHKROJ-GUBZILKMSA-N 0.000 description 1
- UZSQXCMNUPKLCC-FJXKBIBVSA-N Arg-Thr-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O UZSQXCMNUPKLCC-FJXKBIBVSA-N 0.000 description 1
- JJGRJMKUOYXZRA-LPEHRKFASA-N Asn-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)N)N)C(=O)O JJGRJMKUOYXZRA-LPEHRKFASA-N 0.000 description 1
- XVVOVPFMILMHPX-ZLUOBGJFSA-N Asn-Asp-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O XVVOVPFMILMHPX-ZLUOBGJFSA-N 0.000 description 1
- OKZOABJQOMAYEC-NUMRIWBASA-N Asn-Gln-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OKZOABJQOMAYEC-NUMRIWBASA-N 0.000 description 1
- GOPFMQJUQDLUFW-LKXGYXEUSA-N Asn-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O GOPFMQJUQDLUFW-LKXGYXEUSA-N 0.000 description 1
- PUUPMDXIHCOPJU-HJGDQZAQSA-N Asn-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O PUUPMDXIHCOPJU-HJGDQZAQSA-N 0.000 description 1
- CPYHLXSGDBDULY-IHPCNDPISA-N Asn-Trp-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O CPYHLXSGDBDULY-IHPCNDPISA-N 0.000 description 1
- ZLGKHJHFYSRUBH-FXQIFTODSA-N Asp-Arg-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLGKHJHFYSRUBH-FXQIFTODSA-N 0.000 description 1
- QOVWVLLHMMCFFY-ZLUOBGJFSA-N Asp-Asp-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O QOVWVLLHMMCFFY-ZLUOBGJFSA-N 0.000 description 1
- QXHVOUSPVAWEMX-ZLUOBGJFSA-N Asp-Asp-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O QXHVOUSPVAWEMX-ZLUOBGJFSA-N 0.000 description 1
- XAJRHVUUVUPFQL-ACZMJKKPSA-N Asp-Glu-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O XAJRHVUUVUPFQL-ACZMJKKPSA-N 0.000 description 1
- RQYMKRMRZWJGHC-BQBZGAKWSA-N Asp-Gly-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)O)N RQYMKRMRZWJGHC-BQBZGAKWSA-N 0.000 description 1
- JJQGZGOEDSSHTE-FOHZUACHSA-N Asp-Thr-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O JJQGZGOEDSSHTE-FOHZUACHSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- KKZHXOOZHFABQQ-UWJYBYFXSA-N Cys-Ala-Tyr Chemical compound SC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 KKZHXOOZHFABQQ-UWJYBYFXSA-N 0.000 description 1
- RRIJEABIXPKSGP-FXQIFTODSA-N Cys-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CS RRIJEABIXPKSGP-FXQIFTODSA-N 0.000 description 1
- YZFCGHIBLBDZDA-ZLUOBGJFSA-N Cys-Asp-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O YZFCGHIBLBDZDA-ZLUOBGJFSA-N 0.000 description 1
- ASHTVGGFIMESRD-LKXGYXEUSA-N Cys-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CS)N)O ASHTVGGFIMESRD-LKXGYXEUSA-N 0.000 description 1
- ATPDEYTYWVMINF-ZLUOBGJFSA-N Cys-Cys-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O ATPDEYTYWVMINF-ZLUOBGJFSA-N 0.000 description 1
- HHABWQIFXZPZCK-ACZMJKKPSA-N Cys-Gln-Ser Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N HHABWQIFXZPZCK-ACZMJKKPSA-N 0.000 description 1
- CVLIHKBUPSFRQP-WHFBIAKZSA-N Cys-Gly-Ala Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](C)C(O)=O CVLIHKBUPSFRQP-WHFBIAKZSA-N 0.000 description 1
- GUKYYUFHWYRMEU-WHFBIAKZSA-N Cys-Gly-Asp Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O GUKYYUFHWYRMEU-WHFBIAKZSA-N 0.000 description 1
- RWAZRMXTVSIVJR-YUMQZZPRSA-N Cys-Gly-His Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CC1=CNC=N1)C(O)=O RWAZRMXTVSIVJR-YUMQZZPRSA-N 0.000 description 1
- OXOQBEVULIBOSH-ZDLURKLDSA-N Cys-Gly-Thr Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O OXOQBEVULIBOSH-ZDLURKLDSA-N 0.000 description 1
- ODDOYXKAHLKKQY-MMWGEVLESA-N Cys-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CS)N ODDOYXKAHLKKQY-MMWGEVLESA-N 0.000 description 1
- IZUNQDRIAOLWCN-YUMQZZPRSA-N Cys-Leu-Gly Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CS)N IZUNQDRIAOLWCN-YUMQZZPRSA-N 0.000 description 1
- SNHRIJBANHPWMO-XGEHTFHBSA-N Cys-Met-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)N)O SNHRIJBANHPWMO-XGEHTFHBSA-N 0.000 description 1
- HEPLXMBVMCXTBP-QWRGUYRKSA-N Cys-Phe-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O HEPLXMBVMCXTBP-QWRGUYRKSA-N 0.000 description 1
- JIVJQYNNAYFXDG-LKXGYXEUSA-N Cys-Thr-Asn Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O JIVJQYNNAYFXDG-LKXGYXEUSA-N 0.000 description 1
- BOMGEMDZTNZESV-QWRGUYRKSA-N Cys-Tyr-Gly Chemical compound SC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 BOMGEMDZTNZESV-QWRGUYRKSA-N 0.000 description 1
- VRJZMZGGAKVSIQ-SRVKXCTJSA-N Cys-Tyr-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O VRJZMZGGAKVSIQ-SRVKXCTJSA-N 0.000 description 1
- VOLVNCMGXWDDQY-LPEHRKFASA-N Gln-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N)C(=O)O VOLVNCMGXWDDQY-LPEHRKFASA-N 0.000 description 1
- HMIXCETWRYDVMO-GUBZILKMSA-N Gln-Pro-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O HMIXCETWRYDVMO-GUBZILKMSA-N 0.000 description 1
- JVSBYEDSSRZQGV-GUBZILKMSA-N Glu-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCC(O)=O JVSBYEDSSRZQGV-GUBZILKMSA-N 0.000 description 1
- FLQAKQOBSPFGKG-CIUDSAMLSA-N Glu-Cys-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CCCN=C(N)N FLQAKQOBSPFGKG-CIUDSAMLSA-N 0.000 description 1
- QQLBPVKLJBAXBS-FXQIFTODSA-N Glu-Glu-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O QQLBPVKLJBAXBS-FXQIFTODSA-N 0.000 description 1
- PXXGVUVQWQGGIG-YUMQZZPRSA-N Glu-Gly-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N PXXGVUVQWQGGIG-YUMQZZPRSA-N 0.000 description 1
- OPAINBJQDQTGJY-JGVFFNPUSA-N Glu-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCC(=O)O)N)C(=O)O OPAINBJQDQTGJY-JGVFFNPUSA-N 0.000 description 1
- VGUYMZGLJUJRBV-YVNDNENWSA-N Glu-Ile-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O VGUYMZGLJUJRBV-YVNDNENWSA-N 0.000 description 1
- OGCIHJPYKVSMTE-YUMQZZPRSA-N Gly-Arg-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O OGCIHJPYKVSMTE-YUMQZZPRSA-N 0.000 description 1
- GGEJHJIXRBTJPD-BYPYZUCNSA-N Gly-Asn-Gly Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O GGEJHJIXRBTJPD-BYPYZUCNSA-N 0.000 description 1
- BPQYBFAXRGMGGY-LAEOZQHASA-N Gly-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CN BPQYBFAXRGMGGY-LAEOZQHASA-N 0.000 description 1
- CCQOOWAONKGYKQ-BYPYZUCNSA-N Gly-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)CN CCQOOWAONKGYKQ-BYPYZUCNSA-N 0.000 description 1
- WZSHYFGOLPXPLL-RYUDHWBXSA-N Gly-Phe-Glu Chemical compound NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O WZSHYFGOLPXPLL-RYUDHWBXSA-N 0.000 description 1
- FNXSYBOHALPRHV-ONGXEEELSA-N Gly-Val-Lys Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN FNXSYBOHALPRHV-ONGXEEELSA-N 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- OZBDSFBWIDPVDA-BZSNNMDCSA-N His-His-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC3=CN=CN3)N OZBDSFBWIDPVDA-BZSNNMDCSA-N 0.000 description 1
- JBSLJUPMTYLLFH-MELADBBJSA-N His-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC3=CN=CN3)N)C(=O)O JBSLJUPMTYLLFH-MELADBBJSA-N 0.000 description 1
- NBJAAWYRLGCJOF-UGYAYLCHSA-N Ile-Asp-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N NBJAAWYRLGCJOF-UGYAYLCHSA-N 0.000 description 1
- QRTVJGKXFSYJGW-KBIXCLLPSA-N Ile-Glu-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N QRTVJGKXFSYJGW-KBIXCLLPSA-N 0.000 description 1
- KYLIZSDYWQQTFM-PEDHHIEDSA-N Ile-Ile-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CCCN=C(N)N KYLIZSDYWQQTFM-PEDHHIEDSA-N 0.000 description 1
- AFERFBZLVUFWRA-HTFCKZLJSA-N Ile-Ile-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)O)N AFERFBZLVUFWRA-HTFCKZLJSA-N 0.000 description 1
- NURNJECQNNCRBK-FLBSBUHZSA-N Ile-Thr-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NURNJECQNNCRBK-FLBSBUHZSA-N 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- MMEDVBWCMGRKKC-GARJFASQSA-N Leu-Asp-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N MMEDVBWCMGRKKC-GARJFASQSA-N 0.000 description 1
- VPKIQULSKFVCSM-SRVKXCTJSA-N Leu-Gln-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VPKIQULSKFVCSM-SRVKXCTJSA-N 0.000 description 1
- WXUOJXIGOPMDJM-SRVKXCTJSA-N Leu-Lys-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O WXUOJXIGOPMDJM-SRVKXCTJSA-N 0.000 description 1
- RTIRBWJPYJYTLO-MELADBBJSA-N Leu-Lys-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N RTIRBWJPYJYTLO-MELADBBJSA-N 0.000 description 1
- MVHXGBZUJLWZOH-BJDJZHNGSA-N Leu-Ser-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O MVHXGBZUJLWZOH-BJDJZHNGSA-N 0.000 description 1
- LFSQWRSVPNKJGP-WDCWCFNPSA-N Leu-Thr-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(O)=O LFSQWRSVPNKJGP-WDCWCFNPSA-N 0.000 description 1
- VEGLGAOVLFODGC-GUBZILKMSA-N Lys-Glu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O VEGLGAOVLFODGC-GUBZILKMSA-N 0.000 description 1
- OIQSIMFSVLLWBX-VOAKCMCISA-N Lys-Leu-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OIQSIMFSVLLWBX-VOAKCMCISA-N 0.000 description 1
- RIPJMCFGQHGHNP-RHYQMDGZSA-N Lys-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)N)O RIPJMCFGQHGHNP-RHYQMDGZSA-N 0.000 description 1
- AHZNUGRZHMZGFL-GUBZILKMSA-N Met-Arg-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CCCNC(N)=N AHZNUGRZHMZGFL-GUBZILKMSA-N 0.000 description 1
- IYXDSYWCVVXSKB-CIUDSAMLSA-N Met-Asn-Glu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O IYXDSYWCVVXSKB-CIUDSAMLSA-N 0.000 description 1
- HLYIDXAXQIJYIG-CIUDSAMLSA-N Met-Gln-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HLYIDXAXQIJYIG-CIUDSAMLSA-N 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- CSDMCMITJLKBAH-SOUVJXGZSA-N Phe-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O CSDMCMITJLKBAH-SOUVJXGZSA-N 0.000 description 1
- MJQFZGOIVBDIMZ-WHOFXGATSA-N Phe-Ile-Gly Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)O MJQFZGOIVBDIMZ-WHOFXGATSA-N 0.000 description 1
- CDHURCQGUDNBMA-UBHSHLNASA-N Phe-Val-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 CDHURCQGUDNBMA-UBHSHLNASA-N 0.000 description 1
- SSSFPISOZOLQNP-GUBZILKMSA-N Pro-Arg-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O SSSFPISOZOLQNP-GUBZILKMSA-N 0.000 description 1
- CYQQWUPHIZVCNY-GUBZILKMSA-N Pro-Arg-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O CYQQWUPHIZVCNY-GUBZILKMSA-N 0.000 description 1
- CJZTUKSFZUSNCC-FXQIFTODSA-N Pro-Asp-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1 CJZTUKSFZUSNCC-FXQIFTODSA-N 0.000 description 1
- UPJGUQPLYWTISV-GUBZILKMSA-N Pro-Gln-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UPJGUQPLYWTISV-GUBZILKMSA-N 0.000 description 1
- APIAILHCTSBGLU-JYJNAYRXSA-N Pro-Met-Phe Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@@H]2CCCN2 APIAILHCTSBGLU-JYJNAYRXSA-N 0.000 description 1
- OWQXAJQZLWHPBH-FXQIFTODSA-N Pro-Ser-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O OWQXAJQZLWHPBH-FXQIFTODSA-N 0.000 description 1
- BKOKTRCZXRIQPX-ZLUOBGJFSA-N Ser-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N BKOKTRCZXRIQPX-ZLUOBGJFSA-N 0.000 description 1
- XVAUJOAYHWWNQF-ZLUOBGJFSA-N Ser-Asn-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O XVAUJOAYHWWNQF-ZLUOBGJFSA-N 0.000 description 1
- TYYBJUYSTWJHGO-ZKWXMUAHSA-N Ser-Asn-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O TYYBJUYSTWJHGO-ZKWXMUAHSA-N 0.000 description 1
- MMAPOBOTRUVNKJ-ZLUOBGJFSA-N Ser-Asp-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CO)N)C(=O)O MMAPOBOTRUVNKJ-ZLUOBGJFSA-N 0.000 description 1
- UFKPDBLKLOBMRH-XHNCKOQMSA-N Ser-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)N)C(=O)O UFKPDBLKLOBMRH-XHNCKOQMSA-N 0.000 description 1
- RQXDSYQXBCRXBT-GUBZILKMSA-N Ser-Met-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RQXDSYQXBCRXBT-GUBZILKMSA-N 0.000 description 1
- PPCZVWHJWJFTFN-ZLUOBGJFSA-N Ser-Ser-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPCZVWHJWJFTFN-ZLUOBGJFSA-N 0.000 description 1
- FZXOPYUEQGDGMS-ACZMJKKPSA-N Ser-Ser-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O FZXOPYUEQGDGMS-ACZMJKKPSA-N 0.000 description 1
- WUXCHQZLUHBSDJ-LKXGYXEUSA-N Ser-Thr-Asp Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC(O)=O)C(O)=O WUXCHQZLUHBSDJ-LKXGYXEUSA-N 0.000 description 1
- VLMIUSLQONKLDV-HEIBUPTGSA-N Ser-Thr-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VLMIUSLQONKLDV-HEIBUPTGSA-N 0.000 description 1
- YXEYTHXDRDAIOJ-CWRNSKLLSA-N Ser-Trp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CO)N)C(=O)O YXEYTHXDRDAIOJ-CWRNSKLLSA-N 0.000 description 1
- SYCFMSYTIFXWAJ-DCAQKATOSA-N Ser-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CO)N SYCFMSYTIFXWAJ-DCAQKATOSA-N 0.000 description 1
- NLSNVZAREYQMGR-HJGDQZAQSA-N Thr-Asp-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NLSNVZAREYQMGR-HJGDQZAQSA-N 0.000 description 1
- UZJDBCHMIQXLOQ-HEIBUPTGSA-N Thr-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O UZJDBCHMIQXLOQ-HEIBUPTGSA-N 0.000 description 1
- WVVOFCVMHAXGLE-LFSVMHDDSA-N Thr-Phe-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(O)=O WVVOFCVMHAXGLE-LFSVMHDDSA-N 0.000 description 1
- SGAOHNPSEPVAFP-ZDLURKLDSA-N Thr-Ser-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SGAOHNPSEPVAFP-ZDLURKLDSA-N 0.000 description 1
- MNMYOSZWCKYEDI-JRQIVUDYSA-N Tyr-Asp-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MNMYOSZWCKYEDI-JRQIVUDYSA-N 0.000 description 1
- XJPXTYLVMUZGNW-IHRRRGAJSA-N Tyr-Pro-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O XJPXTYLVMUZGNW-IHRRRGAJSA-N 0.000 description 1
- LHADRQBREKTRLR-DCAQKATOSA-N Val-Cys-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)N LHADRQBREKTRLR-DCAQKATOSA-N 0.000 description 1
- OXGVAUFVTOPFFA-XPUUQOCRSA-N Val-Gly-Cys Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N OXGVAUFVTOPFFA-XPUUQOCRSA-N 0.000 description 1
- WJVLTYSHNXRCLT-NHCYSSNCSA-N Val-His-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(=O)O)C(=O)O)N WJVLTYSHNXRCLT-NHCYSSNCSA-N 0.000 description 1
- RYQUMYBMOJYYDK-NHCYSSNCSA-N Val-Pro-Glu Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)O)N RYQUMYBMOJYYDK-NHCYSSNCSA-N 0.000 description 1
- JVGDAEKKZKKZFO-RCWTZXSCSA-N Val-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)O JVGDAEKKZKKZFO-RCWTZXSCSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 108010045350 alanyl-tyrosyl-alanine Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 108010069926 arginyl-glycyl-serine Proteins 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 108010038633 aspartylglutamate Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010062266 glycyl-glycyl-argininal Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 108010031424 isoleucyl-prolyl-proline Proteins 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 108010073093 leucyl-glycyl-glycyl-glycine Proteins 0.000 description 1
- 108010090333 leucyl-lysyl-proline Proteins 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 108010012581 phenylalanylglutamate Proteins 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种用于检测人Dsg1 IgG抗体的ELISA试剂盒及其应用。所述的试剂盒中含有Dsg1微孔条带，所述的Dsg1微孔条带中分别包被有SEQ ID NO.1‑25所示的多肽或所述多肽的混合物。优选的，所述的试剂盒中还含有标准血清1和2、酶标抗体、稀释液、反应缓冲液、清洗缓冲液、酶基质液以及终止液。本发明利用多个抗原多肽来替代长片段的完整蛋白作为ELISA的包被蛋白，在充分保障了抗体识别的抗原表位的同时，节约了大量的成本，且相对于重组蛋白而言，敏感性会更高。本发明利用ELISA方法检测人Dsg1 IgG抗体，相对于现有的免疫印迹法，更容易应用于临床对落叶型天疱疮和寻常型天疱疮的诊断。
Description
技术领域
本发明涉及一种ELISA试剂盒及其应用，特别涉及一种用于检测人Desmoglein 1(Dsg1)IgG抗体的ELISA试剂盒及其应用。本发明属于医药技术领域。
背景技术
人皮肤自身免疫性水疱病主要分为两类，分别是天疱疮和类天疱疮。天疱疮的诊断主要依赖于实验室对Dsg1和Dsg3自身抗体的检测。其中可疑天疱疮患者如果只检测到Dsg1的自身抗体就会被诊断为落叶型天疱疮(Pemphigus foliaceus，PF)，如果同时检测到Dsg1和Dsg3的自身抗体就会被诊断为寻常型天疱疮(Pemphigus vulgaris，PV)，如果只检测到Dsg3的自身抗体就会被诊断为黏膜优位的寻常型天疱疮。
现有的检测人Dsg1的IgG自身抗体的方法主要是免疫印迹法和ELISA法两种。免疫印迹法主要使用的是表皮抽提物作为抗原。表皮抽提物的制备过程非常复杂，目前全世界也只有非常专业的实验室才能制备，重组蛋白获得较容易，但是费用较高，最关键的问题是免疫印迹的方法比较复杂，不适宜在临床进行广泛应用。目前的商品化的检测Dsg1 IgG自身抗体的ELISA试剂盒因其只针对Dsg1的胞外区进行检测，这个区域被认为天疱疮(pemphigus)，尤其是落叶型天疱疮(Pemphigus foliaceus，PF)患者血清中的自身抗体主要识别的区域。但是，近期发现，一些天疱疮患者体内还存在着识别Dsg1胞内区的抗体，而目前商品化识别Dsg1 IgG抗体检测试剂盒对识别Dsg1其它区域的抗体无法检出，会出现假阴性的情况，从而影响患者的诊断及后续的治疗，不能满足未来天疱疮的诊断需求。
有鉴于此，本发明提出了一种新型的Dsg1 IgG抗体检测ELISA试剂盒，该试剂盒能够对识别Dsg1全长的全部抗原表位的抗体进行检测，提高了自身抗体的检出率，进而提高了临床上对天疱疮的诊断准确性。
发明内容
本发明的目的在于提供一种用于检测人Dsg1 IgG抗体的ELISA试剂盒及其应用。
为了达到上述目的，本发明采用了以下技术手段：
本发明的一种用于检测人Dsg1 IgG抗体的ELISA试剂盒，所述的试剂盒中含有Dsg1微孔条带，所述的Dsg1微孔条带中分别包被有SEQ ID NO.1-25所示的多肽或所述多肽的混合物。
其中，优选的，所述的试剂盒中还含有标准血清1、标准血清2、酶标抗体、稀释液、反应缓冲液、清洗缓冲液、酶基质液以及终止液。
其中，优选的，所述的标准血清1为含0.05％w/v叠氮钠的反应缓冲液；所述的标准血清2为含有100U/ml的Dsg1 IgG抗体以及0.05％w/v叠氮钠的反应缓冲液；所述的酶标抗体为辣根过氧化物酶标记的兔抗人IgG抗体；所述的反应缓冲液为含0.05％v/v Tween20和0.05％w/vNaN3的1xPBS，所述的清洗缓冲液为含0.5％v/vTween20的10xPBS；所述的酶基质液为TMB显色液；所述的终止液为0.5N盐酸溶液。
其中，优选的，所述的含有Dsg1微孔条带通过以下方法制备得到：
1)将SEQ ID NO.1-25所示的多肽分别用PBS溶解，得到储存浓度为4mg/ml的多肽溶液，所有溶解后的多肽等体积混合，获得4mg/ml的多肽混合物，包被前使用PBS进行1000倍稀释，使得多肽混合物的终浓度达到4μg/ml；取96孔板进行抗原多肽的包被，每孔加入多肽混合物100μl，4℃进行包被12-16h；或
2)将SEQ ID NO.1-25所示的多肽分别用PBS溶解，得到储存浓度为4mg/ml的多肽溶液，包被前分别使用PBS进行1000倍稀释，使得多肽的终浓度达到4μg/ml；取96孔板进行抗原多肽的包被，每孔分别加入一种多肽溶液100μl，4℃进行包被12-16h。
本发明的一种人Dsg1的IgG抗体检测试剂盒(ELISA)，利用ELISA方法定性测定血清中的Dsg1的IgG抗体。检测时，患者血清和标准血清加入到包被有Dsg1抗原多肽的微孔条带，Dsg1的IgG抗体与抗原结合。洗涤后，去除未结合的血清蛋白，然后微孔中加入辣根过氧化物酶标记的抗人IgG抗体与人IgG结合，洗涤后，加入辣根过氧化物酶底物与辣根过氧化物酶反应，最后通过加入酸溶液终止酶反应。使用酶标仪测定吸光度，量化检测结果。
其中，优选的，所述的用于检测人Dsg1 IgG抗体时，按照以下步骤进行：
(1)试剂准备
实验前，将所有检测材料置于室温下(20-30℃)，根据需要用蒸馏水稀释适量的清洗缓冲液；
(2)样本准备
1:50稀释每个患者血清：10μl血清加500μl反应缓冲液，混匀；
(3)检测步骤
1)微孔条带加入100μl稀释后样本，室温下孵育60分钟；
2)洗涤微孔条带：使用200μl/孔稀释后的清洗缓冲液，洗涤4次；
3)加入100μl/孔酶标记抗体液，室温下孵育45分钟；
4)洗涤微孔条带：使用200μl/孔稀释后的清洗缓冲液，洗涤4次；
5)加入100μl/孔酶基质液，室温下孵育30分钟；
6)加入100μl/孔终止液；
7)读取吸光度(450nm)；
8)结果计算和判定
单位值(U/ml)计算公式：
(A450<样品>-A450<标准血清1>)*100/(A450<标准血清2>-A450<标准血清1>)
判定标准：单位值<25为阴性；单位值≥25为阳性。
质量控制：每个检测结果必须符合下列条件，否则结果无效：
标准血清1的OD450小于等于0.100
标准血清2的OD450大于等于0.500。
进一步的，本发明还提出了所述的ELISA试剂盒在制备检测Dsg1 IgG抗体的试剂中的用途。以及所述的ELISA试剂盒在制备检测或诊断落叶型天疱疮和寻常型天疱疮的试剂中的用途。
相较于现有技术，本发明的有益效果是：
1)本发明利用多个Dsg1抗原多肽来替代全长片段的完整蛋白作为ELISA的包被蛋白，在充分保障了抗体识别的抗原表位的同时，节约了大量的成本。如果合成人Dsg1的全长蛋白，或者分几段进行合成，然后混合在一起使用，作为包被蛋白，进行ELISA检测，也是一种办法。但是这样做的话，会导致2个问题：(1)成本大量提高；(2)需要包被更大量的蛋白，且可能会导致检测敏感性降低(因为包被的抗原表位相当于被稀释了)。
2)采用ELISA方法检测Dsg1 IgG抗体，相对于现有的免疫印迹法，ELISA方法更容易应用于临床对天疱疮的诊断；
3)本试剂盒的微孔条带中包被的是Dsg1的全长的抗原多肽，相对于Dsg1重组蛋白等而言，成本低，且含有全部需要的抗原位点，因为包被的抗原表位相对更多，所以敏感性会更高。
具体实施方式
下面通过实验并结合实施例对本发明做进一步说明，应该理解的是，这些实施例仅用于例证的目的，决不限制本发明的保护范围。
实施例1用于检测Dsg1 IgG抗体的ELISA试剂盒的制备
1、组成：
ELISA试剂盒包括：
(1)Dsg1微孔条带(48孔)
(2)0U/ml的标准血清1(含0.05％叠氮钠w/v的反应缓冲液，1.5ml)
(3)100U/ml的标准血清2(Dsg1 IgG自身抗体阳性的患者血清稀释于含0.05％w/v叠氮钠的反应缓冲液，1.5ml)
(4)酶标抗体(辣根过氧化物酶标记的兔抗人IgG抗体，8ml)
(5)1x反应缓冲液(含0.05％v/vTween20和0.05％w/vNaN3的0.01M PBS，50ml)
(6)10x清洗缓冲液(含0.5％v/vTween20的0.1M PBS，100ml)
(7)酶基质液(即用型TMB显色液，8ml)
(8)终止液(0.5N盐酸溶液，8ml)
2、Dsg1微孔条带的包被
(1)包被的材料包括如下表1所示的25个Dsg1抗原多肽：
表1 25个Dsg1抗原多肽
(2)多肽溶解和包被
表1中的每个多肽用PBS溶解，储存浓度为4mg/ml。所有溶解后的多肽等体积混合，获得4mg/ml的多肽混合物。包被前使用PBS进行1000倍稀释，使得多肽混合物的终浓度达到4μg/ml。取96孔板进行抗原多肽的包被，每孔加入多肽混合物(4μg/ml)100μl，4℃过夜(12-16小时)进行包被。
3、检测方法
(1)试剂准备
实验前，将所有检测材料置于室温下(20-30℃)；根据需要用蒸馏水稀释适量的清洗缓冲液(1:10)。
(2)样本准备
1:50稀释每个患者血清：10μl血清加500μl反应缓冲液，混匀。
(3)检测步骤
1)微孔条带加入100μl稀释后样本(1:50)，室温下(20-30℃)孵育60分钟；
2)洗涤微孔条带：200μl/孔稀释后的清洗缓冲液，洗涤4次；
3)加入100μl/孔酶标记抗体液，室温下(20-30℃)45分钟；
4)洗涤微孔条带：200μl/孔稀释后的清洗缓冲液，洗涤4次；
5)加入100μl/孔酶基质液，室温下(20-30℃)孵育30分钟；
6)加入100μl/孔终止液；
7)读取吸光度(450nm)；
8)结果计算和判定
单位值(U/ml)计算公式：
(A450<样品>-A450<标准血清1>)*100/(A450<标准血清2>-A450<标准血清1>)
判定标准：单位值<25为阴性；单位值≥25为阳性。
质量控制：每个检测结果必须符合下列条件，否则结果无效：
(1)标准血清1的OD450小于等于0.100
(2)标准血清2的OD450大于等于0.500。
实施例2试剂盒的性能指标检测
(1)样本来源
落叶型天疱疮、寻常型天疱疮、大疱性类天疱疮患者血清各50份，一部分来自于日本久留米大学皮肤科，由Takashi Hashimoto教授赠与(收集的来自于日本和世界各地的患者)，另一部分来自于中国的三甲医院皮肤科或者皮肤病专科医院提供的进行皮肤自身免疫性水疱病的血清学诊断后的剩余患者血清。正常人血清300份来自于医院的正常体检的剩余血清。
血清均采用1：50稀释。
(2)特异性和敏感性
将50份落叶型天疱疮患者血清分别使用商品化ELISA试剂盒(MBL公司)以及本发明建立的ELISA试剂盒进行检测，结果发现，使用商品化ELISA试剂盒50份患者血清中有25份是检测到Dsg1抗体阳性的，即为落叶型天疱疮，另外25份检测阴性，但免疫印迹法确认Dsg1抗体阳性的。即商品化试剂盒的检测Dsg1抗体阳性率为50％。
当使用本发明的ELISA试剂盒检测Dsg1抗体的时候，得到的结果显示50份落叶型天疱患者血清中有41份(82％)Dsg1抗体检测阳性，对寻常型天疱疮患者血清中有30份(60％)Dsg1抗体检测阳性，而对大疱性类天疱疮患者血清检测结果均为阴性。结果如下表2所示：
表2
由此可见，相较于商品化ELISA试剂盒，本发明的试剂盒敏感性更高，并且特异性良好。
(3)重复性
对5个样本，分别进行了6次的重复，每个样本重复的CV％值均小于15％。
(4)检测范围
本试剂盒的检测范围为5-150U/ml。
序列表
<110> 钱华
<120> 一种用于检测人Dsg1 IgG抗体的ELISA试剂盒及其应用
<160> 25
<170> SIPOSequenceListing 1.0
<210> 1
<211> 15
<212> PRT
<213> Homo
<400> 1
Cys Phe Gly Asn Asp Asp Arg Thr Asn Thr Glu Pro Asn Thr Lys
1 5 10 15
<210> 2
<211> 15
<212> PRT
<213> Homo sapiens
<400> 2
Arg Gly Ser Asp Arg Asp Gly Gly Ala Asp Gly Met Ser Ala Cys
1 5 10 15
<210> 3
<211> 15
<212> PRT
<213> Homo sapiens
<400> 3
Cys Thr Asn Tyr Asp Thr Ser Thr Thr Ser Thr Asp Ser Ser Gln
1 5 10 15
<210> 4
<211> 15
<212> PRT
<213> Homo sapiens
<400> 4
Cys Tyr Gly Gly Arg Glu Met Gln Asp Leu Gly Gly Gly Glu Arg
1 5 10 15
<210> 5
<211> 15
<212> PRT
<213> Homo sapiens
<400> 5
Cys Gly Ala Pro Arg Ser Ala Ala Gly Phe Glu Pro Val Pro Glu
1 5 10 15
<210> 6
<211> 15
<212> PRT
<213> Homo sapiens
<400> 6
Cys Met Thr Gly Phe Glu Leu Thr Glu Gly Val Lys Thr Ser Gly
1 5 10 15
<210> 7
<211> 15
<212> PRT
<213> Homo sapiens
<400> 7
Cys Gly Thr Leu Arg Arg Asn Ser Met Arg Glu Cys Arg Glu Gly
1 5 10 15
<210> 8
<211> 15
<212> PRT
<213> Homo sapiens
<400> 8
Cys Ala Val Glu Gly Pro Gln Pro Glu Pro Arg Asp Ile Thr Thr
1 5 10 15
<210> 9
<211> 15
<212> PRT
<213> Homo sapiens
<400> 9
Cys Ala Tyr Ala Tyr Ala Asp Glu Asp Glu Gly Arg Pro Ser Asn
1 5 10 15
<210> 10
<211> 15
<212> PRT
<213> Homo sapiens
<400> 10
Cys Asp Thr Leu Lys Pro Ser Val His Val His Asp Asn Arg Pro
1 5 10 15
<210> 11
<211> 15
<212> PRT
<213> Homo sapiens
<400> 11
Cys Asp Ser Arg Thr Gly Lys Leu Thr Leu Lys Asn Lys Val Thr
1 5 10 15
<210> 12
<211> 15
<212> PRT
<213> Homo sapiens
<400> 12
Cys Leu Gly Lys Glu Ser Tyr Pro Asp Leu Asp Pro Ser Trp Pro
1 5 10 15
<210> 13
<211> 15
<212> PRT
<213> Homo sapiens
<400> 13
Cys Gln Ser Thr Glu Pro Val Cys Leu Pro Gln Glu Thr Glu Pro
1 5 10 15
<210> 14
<211> 15
<212> PRT
<213> Homo sapiens
<400> 14
Cys Gly His Met Arg Ser Ser Ser Asp His His Phe Asn Gln Thr
1 5 10 15
<210> 15
<211> 15
<212> PRT
<213> Homo sapiens
<400> 15
Cys Ala Asp Leu His Gly Met Leu Glu Met Pro Asp Leu Arg Asp
1 5 10 15
<210> 16
<211> 15
<212> PRT
<213> Homo sapiens
<400> 16
Cys Tyr Ser Ser Glu Pro Gly Asn Gly Ala Lys Asp Leu Leu Ser
1 5 10 15
<210> 17
<211> 15
<212> PRT
<213> Homo sapiens
<400> 17
Cys Ile Pro Pro Asp Asn Ala Asn Ile Ile Glu Cys Ile Asp Asn
1 5 10 15
<210> 18
<211> 15
<212> PRT
<213> Homo sapiens
<400> 18
Cys Thr Ile Leu Ser Ile Asp Asp Asn Leu Gln Arg Thr Cys Thr
1 5 10 15
<210> 19
<211> 15
<212> PRT
<213> Homo sapiens
<400> 19
Cys Gly Asp Phe Val Ala Thr Asp Leu Asp Thr Gly Arg Pro Ser
1 5 10 15
<210> 20
<211> 15
<212> PRT
<213> Homo sapiens
<400> 20
Asn Trp Phe Glu Ile Glu Met Asn Glu Arg Thr Asn Val Gly Cys
1 5 10 15
<210> 21
<211> 15
<212> PRT
<213> Homo sapiens
<400> 21
Thr Phe Ala Gly Gln Ile Glu Glu Asn Ser Asn Ala Asn Thr Cys
1 5 10 15
<210> 22
<211> 15
<212> PRT
<213> Homo sapiens
<400> 22
Ile Ile Arg Gln Glu Pro Ser Asp Ser Pro Met Phe Ile Ile Cys
1 5 10 15
<210> 23
<211> 14
<212> PRT
<213> Homo sapiens
<400> 23
Cys Cys Ser Phe Ile Gly Glu Asp Leu Asp Asp Ser Phe Leu
1 5 10
<210> 24
<211> 15
<212> PRT
<213> Homo sapiens
<400> 24
Cys Thr Ile His His Pro Arg Glu Ser Ser Asn Val Val Val Thr
1 5 10 15
<210> 25
<211> 15
<212> PRT
<213> Homo sapiens
<400> 25
Asn Ser Asn Leu Leu Glu Ile Arg Val Ile Asp Leu Asp Glu Cys
1 5 10 15
Claims (6)
1.用于检测人Dsg1 IgG抗体的ELISA试剂盒，其特征在于，所述的试剂盒中含有Dsg1微孔条带，所述的Dsg1微孔条带中分别包被有SEQ ID NO.1-25所示的多肽或是所述多肽的混合物。
2.如权利要求1所示的ELISA试剂盒，其特征在于，所述的试剂盒中还含有标准血清1、标准血清2、酶标抗体、稀释液、反应缓冲液、清洗缓冲液、酶基质液以及终止液。
3.如权利要求2所示的ELISA试剂盒，其特征在于，所述的标准血清1为含0.05%w/v叠氮钠的反应缓冲液；所述的标准血清2为含有100 U/ml的Dsg1 IgG抗体以及0.05%w/v叠氮钠的反应缓冲液；所述的酶标抗体为辣根过氧化物酶标记的兔抗人IgG抗体；所述的反应缓冲液为含0.05%v/v Tween20和0.05%w/vNaN3的1xPBS，所述的清洗缓冲液为含0.5%v/vTween20的10xPBS；所述的酶基质液为TMB显色液；所述的终止液为0.5N盐酸溶液。
4.如权利要求1所示的ELISA试剂盒，其特征在于，所述的含有Dsg1微孔条带通过以下方法制备得到：
1）将SEQ ID NO.1-25所示的多肽分别用PBS溶解，得到储存浓度为4mg/ml的多肽溶液，所有溶解后的多肽等体积混合，获得4mg/ml的多肽混合物，包被前使用PBS进行1000倍稀释，使得多肽混合物的终浓度达到4µg/ml；取96孔板进行抗原多肽的包被，每孔加入多肽混合物100µl，4℃进行包被12-16h；或
2）将SEQ ID NO.1-25所示的多肽分别用PBS溶解，得到储存浓度为4mg/ml的多肽溶液，包被前分别使用PBS进行1000倍稀释，使得多肽的终浓度达到4µg/ml；取96孔板进行抗原多肽的包被，每孔分别加入一种多肽溶液100µl，4℃进行包被12-16h。
5.权利要求1-4任一项所述的ELISA试剂盒在制备检测人Dsg1 IgG抗体的装置中的用途。
6.权利要求1-4任一项所述的ELISA试剂盒在制备检测或诊断落叶型天疱疮和寻常型天疱疮的装置中的用途。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111420932.8A CN114152754B (zh) | 2021-11-26 | 2021-11-26 | 一种用于检测人Dsg1 IgG抗体的ELISA试剂盒及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111420932.8A CN114152754B (zh) | 2021-11-26 | 2021-11-26 | 一种用于检测人Dsg1 IgG抗体的ELISA试剂盒及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114152754A CN114152754A (zh) | 2022-03-08 |
| CN114152754B true CN114152754B (zh) | 2024-03-05 |
Family
ID=80458266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111420932.8A Active CN114152754B (zh) | 2021-11-26 | 2021-11-26 | 一种用于检测人Dsg1 IgG抗体的ELISA试剂盒及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114152754B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114994308A (zh) * | 2022-05-07 | 2022-09-02 | 浙江大学 | 一种检测抗Desmoglein 1-IgG抗体的试剂盒 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101980022A (zh) * | 2009-01-13 | 2011-02-23 | 欧莱雅 | 可溶性的桥粒芯糖蛋白i蛋白物质用于筛选抗衰老活性剂的用途 |
| CN106573030A (zh) * | 2014-05-16 | 2017-04-19 | 因特穆内公司 | Lpa相关蛋白和rna表达 |
| CN107074929A (zh) * | 2014-05-02 | 2017-08-18 | 宾夕法尼亚大学董事会 | 嵌合自身抗体受体t细胞的组合物和方法 |
-
2021
- 2021-11-26 CN CN202111420932.8A patent/CN114152754B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101980022A (zh) * | 2009-01-13 | 2011-02-23 | 欧莱雅 | 可溶性的桥粒芯糖蛋白i蛋白物质用于筛选抗衰老活性剂的用途 |
| CN107074929A (zh) * | 2014-05-02 | 2017-08-18 | 宾夕法尼亚大学董事会 | 嵌合自身抗体受体t细胞的组合物和方法 |
| CN113604491A (zh) * | 2014-05-02 | 2021-11-05 | 宾夕法尼亚大学董事会 | 嵌合自身抗体受体t细胞的组合物和方法 |
| CN106573030A (zh) * | 2014-05-16 | 2017-04-19 | 因特穆内公司 | Lpa相关蛋白和rna表达 |
Non-Patent Citations (2)
| Title |
|---|
| Hua Qian 等.Anti-human serum albumin autoantibody may be involved in the pathogenesis of autoimmune bullous skin diseases.The FASEB Journal.2020,第34卷全文. * |
| Taihei Hayakawa等.Diagnosis of oral mucous membrane pemphigoid by means of combined serologic testing.ORAL AND MAXILLOFACIAL PATHOLOGY.2014,第117卷全文. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114152754A (zh) | 2022-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019148754A1 (zh) | 一种pla2r抗体的检测试纸条及检测方法 | |
| KR101431062B1 (ko) | 유방암 진단용 다중 바이오마커 세트, 이의 검출 방법 및 이에 대한 항체를 포함하는 유방암 진단키트 | |
| WO2019148753A1 (zh) | 一种thsd7a抗体的检测试纸条及检测方法 | |
| EP3364193B1 (en) | Improved assay for the diagnosis of peanut allergy | |
| EP3859332B1 (en) | Glycated hemoglobin (%) assay method | |
| CN108414766A (zh) | 用于定量检测糖尿病自身抗体的试剂盒及其应用 | |
| CN114152754B (zh) | 一种用于检测人Dsg1 IgG抗体的ELISA试剂盒及其应用 | |
| CN114152753B (zh) | 一种用于检测人Dsg3 IgG抗体的ELISA试剂盒及其应用 | |
| CN114236132B (zh) | 一种用于检测人BP180 IgG抗体的ELISA试剂盒及其应用 | |
| US20110014626A1 (en) | Methods for measuring the insulin receptor alpha subunit | |
| CN110297093B (zh) | 一种检测人免疫球蛋白g4的方法和试剂盒 | |
| US20100240076A1 (en) | Immunoassay involving mutant antigens to reduce unspecific binding | |
| CN113917151B (zh) | 一种用于检测人integrin β4 IgG抗体的ELISA试剂盒及其应用 | |
| CN110672854A (zh) | 一种用于血清学诊断IgA肾病的分子探针 | |
| CN111398600B (zh) | 一种人源可溶性bcma蛋白的elisa检测试剂盒及其使用方法和应用 | |
| CN115201471A (zh) | 一种用于辅助诊断IgA肾病的标志物组合、其检测试剂盒及肾损伤无创检测方法 | |
| CN111458522B (zh) | 一种用于检测血浆白细胞介素6天然抗体的检测试剂、试剂盒及其应用 | |
| US20110256641A1 (en) | Methods and Systems for Detecting Free IgE | |
| Ding et al. | A novel ELISA method to determine human MrgX2 in chronic urticaria | |
| US8697368B2 (en) | Diagnostic marker for lung cancer comprising HPαR as active ingredient | |
| JP3510889B2 (ja) | 糖尿病及び前糖尿症状の診断のための方法 | |
| CN118393148A (zh) | 一种检测人lamininγ1 IgG抗体的ELISA试剂盒及其应用 | |
| CN116087507A (zh) | 人integrinβ4自身抗体检测ELISA试剂盒 | |
| CN115856319B (zh) | 一种可溶性生长刺激表达基因2蛋白测定试剂盒及其制备方法和应用 | |
| JP7523129B2 (ja) | ヘリコバクター・ピロリ菌株の同定方法、および同定用キット |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |